. Author manuscript; available in PMC: 2024 Mar 1.

Published in final edited form as: Oncogene. 2018 Apr 6;37(27):3672–3685. doi: 10.1038/s41388-018-0156-9

Table 3.

Receptor kinase inhibition

Compound	IC50 (nM)
	ALK2/ACVR1	ALK3/BMPR1A	ALK6/BMPR1B	BMPR2	ALK5/TGFβR1	TGFβR2
DMH2⁽²⁾	23	92	43	7,950	1690	193
JL5	1	<5	2	8,510	440	40
JL12	2,690	8,690	9,310	>10,000	—	3,670

From: Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer